Observational studyAsian Pacific journal of cancer prevention : APJCP2025
Validation of Steroid-Sparing Therapy in Patients Receiving Oxaliplatin-based Chemotherapy: A before-and-after Prospective Observational Study.
Observational study in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAlthough steroids are useful antiemetics, various moderate-to-severe chemotherapy-induced adverse events are observed. Although steroid-sparing antiemetic therapy is beneficial for moderate emetic risk, studies on only oxaliplatin-based regimen have not been fully evaluated. Therefore, this prospective observational study aimed to assess the usefulness of steroid-sparing antiemetic therapy for the second and subsequent courses of chemotherapy.
methodsEligible patients who received a moderate emetic risk oxaliplatin-based chemotherapy regimen at Komaki City Hospital between January 2019 and March 2022 were switched to steroid-sparing antiemetic therapy after the second course. Steroid-sparing antiemetic therapy consisted of switching from granisetron to palonosetron on day 1 and discontinuing steroids on days 2-3. Complete response (CR; no emesis and no rescue medication), nausea and vomiting incidence, rescue use, and food intake were recorded by a pharmacist before the next chemotherapy session and compared before and after steroid-sparing antiemetic therapy.
resultsIn total, 10 patients were included with a median age of 74 years; six were male. CR rate was 70.0% before and 80.0% after steroid-sparing antiemetic therapy, with no significant difference between the two groups. None of the patients experienced worsening nausea or vomiting after steroid-sparing antiemetic therapy. The nausea was transient in all patients with nausea and was managed via abortive rescue treatment with oral administration of metoclopramide. There was no increase in side effects after steroid sparing.
conclusionBased on the proven efficacy and safety in this patient population, we recommend the implementation of steroid-sparing therapy after the second course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.